Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
Bulkmans, N. W. J.; Berkhof, J.; Rozendaal, L.et al.
[en] BACKGROUND: Tests for the DNA of high-risk types of human papillomavirus (HPV) have a higher sensitivity for cervical intraepithelial neoplasia grade 3 or worse (CIN3+) than does cytological testing, but the necessity of such testing in cervical screening has been debated. Our aim was to determine whether the effectiveness of cervical screening improves when HPV DNA testing is implemented. METHODS: Women aged 29-56 years who were participating in the regular cervical screening programme in the Netherlands were randomly assigned to combined cytological and HPV DNA testing or to conventional cytological testing only. After 5 years, combined cytological and HPV DNA testing were done in both groups. The primary outcome measure was the number of CIN3+ lesions detected. Analyses were done by intention to treat. This trial is registered as an International Standard Randomised Controlled Trial, number ISRCTN20781131. FINDINGS: 8575 women in the intervention group and 8580 in the control group were recruited, followed up for sufficient time (> or =6.5 years), and met eligibility criteria for our analyses. More CIN3+ lesions were detected at baseline in the intervention group than in the control group (68/8575 vs 40/8580, 70% increase, 95% CI 15-151; p=0.007). The number of CIN3+ lesions detected in the subsequent round was lower in the intervention group than in the control group (24/8413 vs 54/8456, 55% decrease, 95% CI 28-72; p=0.001). The number of CIN3+ lesions over the two rounds did not differ between groups. INTERPRETATION: The implementation of HPV DNA testing in cervical screening leads to earlier detection of CIN3+ lesions. Earlier detection of such lesions could permit an extension of the screening interval.
Disciplines :
Genetics & genetic processes
Author, co-author :
Bulkmans, N. W. J.
Berkhof, J.
Rozendaal, L.
van Kemenade, F. J.
Boeke, A. J. P.
BULK, Saskia ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
Peto J., Gilham C., Fletcher O., and Matthews F. The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 (2004) 249-256
Sasieni P., Adams J., and Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 89 (2003) 88-93
Bulk S., Visser O., Rozendaal L., Verheijen R., and Meijer C. Incidence and survival rate of women with cervical cancer in the greater Amsterdam area. Br J Cancer 89 (2003) 834-839
Aareleid T., Pukkala E., Thomson H., and Hakama M. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs an unscreened population. Eur J Cancer 29A (1993) 745-749
Nieminen P., Kallio M., and Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 85 (1995) 1017-1021
van den Akker-van Marle M., van Ballegooijen M., van Oortmarssen G., Boer R., and Habbema J. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 94 (2002) 193-204
Sherman M., Lorincz A., Scott D., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
Kjaer S., Hogdall E., Frederiksen K., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66 (2006) 10630-10636
Rozendaal L., Westerga J., van der Linden J., et al. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 53 (2000) 606-611
Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
Cuzick J., Clavel C., Petry K., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
Clavel C., Masure M., Bory J., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84 (2001) 1616-1623
Kulasingam S., Hughes J., Kiviat N., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
Ratnam S., Franco E., and Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 9 (2000) 945-951
Petry K., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88 (2003) 1570-1577
Smith R., Cokkinides V., and Eyre H. American Cancer Society Guidelines for the early detection of cancer, 2005. CA Cancer J Clin 55 (2005) 31-44
Ronco G., Giorgi-Rossi P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7 (2006) 547-555
Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98 (2006) 765-774
Mayrand M., Duarte-Franco E., Coutlee F., et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 119 (2006) 615-623
Kotaniemi-Talonen L., Nieminen P., Anttila A., and Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 93 (2005) 862-867
Kitchener H., Almonte M., Wheeler P., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95 (2006) 56-61
Elfgren K., Rylander E., Radberg T., et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 193 (2005) 650-657
Bulkmans N., Rozendaal L., Voorhorst F., et al. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening. Int J Cancer 110 (2004) 94-101
Bulk S., Van Kemenade F., Rozendaal L., and Meijer C. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 57 (2004) 388-393
van Ballegooijen M., and Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 36 (2000) 2244-2246
Jacobs M., Snijders P., van den Brule A., Helmerhorst T., Meijer C., and Walboomers J. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35 (1997) 791-795
de Sanjose S., Bosch X., Munoz N., et al. Screening for genital human papillomavirus: results from an international validation study on human papillomavirus sampling techniques. Diagn Mol Pathol 8 (1999) 26-31
Jacobs M., Snijders P., Voorhorst F., et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 52 (1999) 498-503
Hopman E., Rozendaal L., Voorhorst F., Walboomers J., Kenemans P., and Helmerhorst T. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 107 (2000) 600-604
Hopman E., Voorhorst F., Kenemans P., Meyer C., and Helmerhorst T. Observer agreement on interpreting colposcopic images of CIN. Gynecol Oncol 58 (1995) 206-209
Anderson M. Premalignant and malignant squamous lesions of the cervix. In: Fox H., and Wells M. (Eds). Obstetrical and gynaecological pathology. 4th edn. (1995), Churchill Livingstone, New York 292-297
Wright T. Precancerous lesions of the cervix. In: Kurman R. (Ed). Blaustein's pathology of the female genital tract. 4th edn. (1995), Springer Verlag, New York 248-257
Willard K., and Critchfield G. Probabilistic analysis of decision trees using symbolic algebra. Med Decis Making 6 (1986) 93-100
Rozendaal L., Walboomers J., van der Linden J., et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 68 (1996) 766-769
Crosbie E., and Kitchener H. Human papillomavirus in cervical screening and vaccination. Clin Sci (Lond) 110 (2006) 543-552
Jacobs M., Walboomers J., Snijders P., et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87 (2000) 221-227
Snijders P., van den Brule A., and Meijer C. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201 (2003) 1-6
Clavel C, Masure M, Putaud I, et al. Hybrid Capture II, a new sensitive test for human papillomavirus detection. Comparison with Hybrid Capture I and PCR results in cervical lesions. J Clin Pathol; 51: 737-40.
Lorincz A., and Richart R. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 127 (2003) 959-968
Munoz N., Bosch F., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
Nobbenhuis M., Walboomers J., Helmerhorst T., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354 (1999) 20-25
Bulk S., Bulkmans N., Berkhof J., et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 121 (2007) 361-367
Hesselink A., Bulkmans N., Berkhof J., Lorincz A., Meijer C., and Snijders P. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 44 (2006) 3680-3685
Brink A., Zielinski G., Steenbergen R., Snijders P., and Meijer C. Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology 16 (2005) 7-12
Stoler M., Castle P., Solomon D., and Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 127 (2007) 335-337
Bos A., van Ballegooijen M., van Oortmarssen G., and Habbema J. Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening. Eur J Cancer 38 (2002) 827-831
Arbyn M., Sasieni P., Meijer C., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 suppl 3 (2006) S78-S89
Franco E. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 31 (2003) 89-96
Ostor A. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12 (1993) 186-192
Ho G., Bierman R., Beardsley L., Chang C., and Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
Khan M., Castle P., Lorincz A., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
Castle P., Wacholder S., Sherman M., et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 95 (2002) 2145-2151